# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0215 |
| Population Package ID | PP-0215 |
| Title | MSI-H/dMMR Gastric Cancer and Immunotherapy |
| Version | 1.0.0 |
| QA Status | PASS — GOLD |
| Final Status | READY FOR INTEGRATION |
| Last Updated | 2026-08-09 |

---

# 1. QA Executive Decision

# PASS

PP-0215 satisfies the approved and locked Decision Batch and the locked Population Package Gold Specification.

The package is structurally complete, clinically bounded, source-grounded, patient-facing, and architecturally distinct from adjacent Population Packages.

---

# 2. Governance Compliance

## 2.1 Source-First Rule

### PASS

PP-0215 production was based first on the project Source Files.

The primary clinical evidence source is the supplied **NCCN Gastric Cancer Version 2.2026**.

Supporting project sources include:

- NCI Gastric Cancer Treatment PDQ;
- NCI Cancer Genetics Risk Assessment and Counseling PDQ;
- ESMO-ASCO Global Curriculum 2023;
- ACS Stomach Cancer;
- ACS Immunotherapy for Stomach Cancer.

No external web evidence was silently substituted for the project evidence base.

---

## 2.2 Approved Decision Batch

### PASS

Production follows the PP-0215 Decision Batch that was explicitly:

> **Approved + Locked by the Project Coordinator.**

No substantive scope decision was reopened during production.

---

## 2.3 Gold Structure

### PASS

The package contains the four mandatory artifacts:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

The artifact structure follows the locked Gold Specification.

---

## 2.4 Gold Depth Integrity

### PASS

The Absolute Gold Depth Rule was treated as mandatory.

The package was not intentionally compacted, shortened, summarized, or reduced to a minimal implementation.

Depth was calibrated relative to the approved Gold reference rather than to a fixed line count.

The package includes:

- substantive clinical knowledge blocks;
- detailed evidence synthesis;
- evidence hierarchy;
- evidence matrix;
- patient-facing interpretation;
- misconception handling;
- Knowledge Graph;
- boundary/delegation;
- evidence gaps;
- traceability;
- QA review.

---

# 3. CKO QA

## 3.1 Metadata

### PASS

The CKO contains:

- CKO ID;
- PP ID;
- title;
- clinical domain;
- population wave;
- version;
- audience;
- reading level;
- status;
- last updated.

---

## 3.2 Educational Objectives

### PASS

Objectives are explicitly aligned with the atomic clinical question:

> What does MSI-H/dMMR mean in gastric cancer, and why does it matter for immunotherapy?

The objectives cover:

- definition;
- phenotype;
- biological rationale;
- biomarker distinctions;
- treatment relevance;
- evidence;
- limitations;
- patient interpretation;
- delegation.

---

## 3.3 Scope

### PASS

Included and excluded scope are explicitly defined.

No substantive overlap is intentionally introduced with:

- MSI/MMR testing;
- PD-L1 testing;
- TMB testing;
- general immunotherapy;
- general immune checkpoint inhibitors;
- response assessment;
- toxicity;
- genetics.

---

## 3.4 Clinical Knowledge Blocks

### PASS

The CKO uses modular knowledge blocks rather than one uninterrupted narrative.

Major blocks include:

- definitions;
- biology;
- phenotype;
- prognostic/predictive distinction;
- biomarker comparisons;
- advanced disease;
- landmark evidence;
- perioperative evidence;
- hereditary bridge;
- patient interpretation;
- misconceptions;
- key messages.

---

## 3.5 Patient-facing Safety

### PASS

The CKO avoids:

- individualized treatment prescriptions;
- guaranteed-response language;
- unsupported certainty;
- equating MSI-H with Lynch syndrome;
- equating MSI-H with TMB-H;
- equating MSI-H with PD-L1 positivity.

---

# 4. Knowledge Passport QA

## 4.1 Identity

### PASS

KP identity and versioning are complete.

---

## 4.2 Classification

### PASS

The KP specifies:

- clinical domain;
- domain code;
- educational level;
- clinical complexity;
- patient journey stage;
- population;
- primary educational question.

---

## 4.3 Runtime Metadata

### PASS

The KP provides:

- intended runtime usage;
- retrieval tags;
- related Population Packages;
- prerequisite;
- related;
- next package relationships.

---

## 4.4 Governance Metadata

### PASS

The KP identifies:

- primary guideline sources;
- evidence classification;
- source provenance;
- governance status;
- QA status.

---

# 5. Primary Evidence Package QA

## 5.1 Clinical Question

### PASS

The primary educational question is explicitly stated and remains atomic.

---

## 5.2 Evidence Hierarchy

### PASS

Evidence is ordered by authority.

The hierarchy gives priority to:

1. NCCN v2.2026;
2. NCI clinical sources;
3. NCI genetics source;
4. ESMO-ASCO;
5. ACS.

---

## 5.3 Evidence Matrix

### PASS

Major clinical claims are explicitly mapped to supporting source classes.

The Evidence Package distinguishes:

- guideline evidence;
- randomized subgroup evidence;
- phase II evidence;
- tumor-agnostic evidence;
- supporting patient-facing evidence.

---

## 5.4 Evidence Integrity

### PASS

The package does not:

- silently merge gastric and non-gastric evidence;
- treat subgroup findings as universal effects;
- treat tumor-agnostic evidence as gastric-specific randomized evidence;
- convert population-level outcomes into individual prognosis.

---

# 6. Clinical Evidence QA

## 6.1 MSI-H/dMMR Treatment Relevance

### PASS

The package accurately reflects the supplied NCCN framework that MSI-H/dMMR is a clinically important treatment-defining context for checkpoint inhibition.

---

## 6.2 Pembrolizumab Evidence

### PASS

The package includes and appropriately contextualizes:

- KEYNOTE-059;
- KEYNOTE-061;
- KEYNOTE-062;
- KEYNOTE-158.

The evidence is not presented as though all studies had identical designs or populations.

---

## 6.3 Nivolumab Evidence

### PASS

The package includes:

- nivolumab + chemotherapy;
- CheckMate-649;
- MSI-H subgroup outcomes;
- PD-L1-independent guideline positioning.

---

## 6.4 Dual Checkpoint Evidence

### PASS

The package includes:

- nivolumab + ipilimumab;
- MSI-H subgroup evidence;
- contrast with MSS disease.

---

## 6.5 Perioperative Evidence

### PASS

The package includes:

- neoadjuvant/perioperative context;
- NEONIPIGA;
- selected pembrolizumab evidence;
- evolving evidence;
- uncertainty around surgery after complete response.

The wording preserves the source-supported concept of selected/useful-in-certain-circumstances treatment rather than universal application.

---

# 7. Biomarker Boundary QA

## 7.1 MSI-H versus PD-L1

### PASS

The package clearly treats them as separate biomarkers.

---

## 7.2 MSI-H versus TMB-H

### PASS

The package explicitly states that they are related but not interchangeable.

---

## 7.3 MSI-H/dMMR versus Lynch Syndrome

### PASS

The package explicitly states that tumor MSI-H/dMMR does not automatically establish hereditary disease.

---

# 8. Adjacent Population Package QA

## PP-0182 — MSI/MMR Testing

### PASS

Testing methodology is excluded.

PP-0215 consumes the established MSI-H/dMMR result and focuses on clinical meaning and treatment relevance.

---

## PP-0213 — Immunotherapy in Gastric Cancer

### PASS

The package is narrower and biomarker-specific.

It does not duplicate the general immunotherapy framework.

---

## PP-0214 — Immune Checkpoint Inhibitors

### PASS

General checkpoint biology and pharmacology are not duplicated as a separate package.

PP-0215 focuses on the MSI-H/dMMR treatment context.

---

## PP-0216 — PD-L1-guided Immunotherapy

### PASS

PD-L1 testing/scoring and PD-L1-specific treatment logic are delegated.

The package only explains the important distinction that selected MSI-H/dMMR treatment options may be independent of PD-L1.

---

## PP-0217 / PP-0218 / PP-0219

### PASS

Detailed response assessment, RECIST, and post-treatment imaging are delegated.

---

## PP-0231

### PASS

Detailed toxicity and supportive-care management are delegated.

---

# 9. Boundary QA

## Core

MSI-H/dMMR gastric-cancer phenotype; clinical meaning; immunotherapy relevance; advanced/metastatic and selected perioperative evidence; landmark trials; patient-facing interpretation.

### PASS

---

## Supporting

TMB relationship; PD-L1 relationship; hereditary bridge; tumor-agnostic evidence; emerging perioperative evidence.

### PASS

---

## Explicitly Excluded

Testing methodology, detailed pharmacology, toxicity, response assessment, imaging, surgery, sequencing, individualized treatment, and detailed resistance.

### PASS

---

## Delegated-to PP

The package identifies the major adjacent and downstream owners.

### PASS

---

# 10. Evidence Gap QA

### PASS

The package explicitly preserves uncertainty concerning:

- optimal perioperative strategy;
- treatment duration;
- surgery after complete response;
- small MSI-H subgroup sizes;
- cross-trial comparability;
- tumor-agnostic versus gastric-specific evidence;
- individual non-response;
- resistance;
- hereditary interpretation.

No unsupported gap-filling was introduced.

---

# 11. Patient-Safety QA

## Safety principle 1

**MSI-H does not guarantee response.**

### PASS

---

## Safety principle 2

**MSI-H/dMMR does not automatically mean Lynch syndrome.**

### PASS

---

## Safety principle 3

**MSI-H/dMMR does not equal PD-L1 positivity.**

### PASS

---

## Safety principle 4

**MSI-H/dMMR does not equal TMB-H.**

### PASS

---

## Safety principle 5

**Population-level trial outcomes are not individualized treatment predictions.**

### PASS

---

## Safety principle 6

**Treatment decisions remain dependent on the complete clinical context.**

### PASS

---

# 12. Knowledge Graph QA

### PASS

The package has a coherent position:

```text
MSI/MMR Testing
       ↓
MSI-H/dMMR Clinical Meaning
       ↓
MSI-H/dMMR-specific Immunotherapy
       ↓
Treatment / Response / Safety Applications
```

Parallel relationships to:

- Immunotherapy in Gastric Cancer;
- Immune Checkpoint Inhibitors;
- PD-L1-guided Immunotherapy;

are explicitly defined.

---

# 13. Artifact Completeness

| Artifact | Present | QA |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

---

# 14. Final Boundary

## Core

MSI-H/dMMR gastric-cancer phenotype; conceptual biology; clinical and prognostic context; immunotherapy rationale; biomarker-treatment relationship; PD-L1-independent treatment relevance in selected contexts; advanced/metastatic evidence; selected neoadjuvant/perioperative evidence; landmark trials; response depth/durability; patient-facing interpretation.

## Supporting

PD-L1 relationship; TMB relationship; tumor-agnostic evidence; hereditary/genetic-counselling bridge; selected emerging perioperative evidence; conceptual resistance.

## Explicitly Excluded

Detailed MSI/MMR testing; PCR/IHC/NGS methodology; detailed MMR biology; PD-L1 testing/scoring; TMB methodology; Lynch syndrome/germline testing; general ICI pharmacology/dosing; detailed toxicity management; formal response criteria; detailed imaging; surgical technique; universal sequencing; individualized treatment; individualized prognosis; detailed resistance mechanisms.

## Delegated-to PP

PP-0182; PP-0183; PP-0192; PP-0213; PP-0214; PP-0216; PP-0217; PP-0218; PP-0219; PP-0231; hereditary/genetic-testing PPs; TMB-specific packages; downstream sequencing/resistance packages.

---

# 15. Reviewer Notes

PP-0215 functions as the **MSI-H/dMMR-specific clinical application node** in the gastric-cancer precision-immunotherapy knowledge graph.

Its principal architectural value is the separation of:

**MSI/MMR testing**

from:

**MSI-H/dMMR clinical meaning**

from:

**general checkpoint-inhibitor biology**

from:

**PD-L1-guided immunotherapy.**

The package deliberately preserves the distinction between:

1. **biomarker detection;**
2. **biomarker interpretation;**
3. **treatment relevance;**
4. **individual treatment decision-making.**

It also preserves the distinction between:

- gastric-specific evidence;
- gastric/EGJ combined evidence;
- tumor-agnostic evidence;
- randomized subgroup evidence;
- phase II perioperative evidence.

This is necessary to prevent overclaiming.

---

# Final Quality Decision

# PASS

PP-0215 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION** and the approved/locked PP-0215 Decision Batch.

The package is:

- structurally complete;
- source-grounded;
- clinically bounded;
- patient-centered;
- evidence-traceable;
- adjacent-package safe;
- Knowledge-Graph compatible;
- compliant with the Absolute Gold Depth Rule.

# QA final status: PASS — GOLD — READY FOR INTEGRATION.
